BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
A phase 3 trial of Durvalumab in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
Overview
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants is a phase 3 interventional study registered as NCT05943106 by AstraZeneca, with 100 participants enrolled, started 2023-08-11 and due to reach its primary completion in 2025-06-16. Interventions recorded: Durvalumab and BCG.
Similar pages
not linked directly; found by shared links- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Shares Parexel, AstraZeneca and the tag pipeline.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialA Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Shares Parexel and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.